Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ICI 182,780 (Faslodex)
ICI 182, 780 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| ICI 182,780 (Faslodex) | DRUG | - |
Inclusion Criteria: * Premenopausal women with SLE * Without life-threatening manifestations * With regular menstrual cyles not on hormones of any kind Exclusion Criteria: For any of the following: * Increase of SLEDAI greater than 12 * If life-threatening manifestations occur * If menstruation ...
Top 20 of 31 competitors
ICI 182,780 is being studied for the treatment of systemic lupus erythematosus (SLE), an autoimmune disease. It is an investigational small molecule developed by AstraZeneca PLC under the ticker AZN. The drug has completed a Phase 2 clinical trial evaluating its efficacy in SLE patients.
ICI 182,780 is being developed by AstraZeneca PLC, which trades under the ticker AZN. The company sponsored a Phase 2 clinical trial of the drug in systemic lupus erythematosus. AstraZeneca is the sole developer listed for this asset.
ICI 182,780 is in Phase 2 development. A Phase 2 clinical trial in systemic lupus erythematosus has been completed. The drug is investigational and has not been approved by the FDA for any indication.
ICI 182,780 has been evaluated in one completed Phase 2 clinical trial, NCT00417430, titled "Efficacy of Faslodex in Treatment of SLE Clinical, Serologic, and Molecular Studies." The trial enrolled 20 female participants aged 16 years and older in the United States and was randomized and double-blind.
Yes, ICI 182,780 is also known as Faslodex. The alternative name Faslodex appears in the title of its Phase 2 clinical trial in systemic lupus erythematosus. Both names refer to the same investigational small molecule developed by AstraZeneca PLC.